凝血酶激活的纤溶抑制物在心脑血管疾病中的作用研究进展

基础医学与临床 ›› 2017, Vol. 37 ›› Issue (2): 261-264.

凝血酶激活的纤溶抑制物在心脑血管疾病中的作用研究进展

李英杰,杨宝学

北京大学医学部基础医学院

收稿日期:2016-03-24 修回日期:2016-05-26 出版日期:2017-02-05 发布日期:2017-01-16
通讯作者: 杨宝学 E-mail:baoxue@bjmu.edu.cn
基金资助:
国家自然科学基金面上项目;国家自然科学基金面上项目;国家自然科学基金面上项目

Research progress of thrombin activatiable fibrinolysis inhibitor in cardiovascular and cerebrovascular diseases

Received:2016-03-24 Revised:2016-05-26 Online:2017-02-05 Published:2017-01-16
Supported by:
the National Natural Science Foundation of China;the National Natural Science Foundation of China;the National Natural Science Foundation of China

摘要/Abstract

摘要： 凝血酶激活的纤溶抑制物(TAFI)是一种能被凝血酶激活的血浆酶原。对凝血和纤溶起调节作用，具有很强的抗纤溶及抗炎活性。其抑制剂有望解决溶栓血管再通时避免出血的风险，同时，研究发现TAFI在脑血栓、动脉粥样硬化等心脑血管疾病的发生发展中起着至关重要的作用。

关键词: 凝血酶激活的纤溶抑制物, 脑血栓, 心血管病

Abstract: Thrombin activatable fibrinolysis inhibitor (TAFI) is a kind of plasma enzymes that can be activated by thrombin. TAFI regulates blood coagulation and fibrinolysis and has a strong fibrinolytic and anti-inflammatory activity. Its inhibitor is expected to avoid the risk of bleeding when thrombolytic recanalization. Also, studies found that TAFI played an important role in the development of cerebral thrombosis; atherosclerosis and so on.

Key words: thrombin activation of fibrinolysis inhibitor (TAFI), cerebral thrombosis, cardiovascular disease

中图分类号:

R966

李英杰杨宝学. 凝血酶激活的纤溶抑制物在心脑血管疾病中的作用研究进展[J]. 基础医学与临床, 2017, 37(2): 261-264.